Key result
Decellularized pulmonary homografts linked to ~74% lower explantation risk versus cryopreserved homografts.
Why the study?
Early results from the prospective ESPOIR Trial indicated excellent results for pulmonary valve replacement using decellularized pulmonary homografts, but midterm performance data were needed.
Does pulmonary valve replacement using decellularized pulmonary homografts improve freedom from explantation compared to cryopreserved homografts?
Population
121 prospectively enrolled patients (and a combined cohort of 319 DPH patients matched to 319 CH patients)
Comparison
Decellularized pulmonary homografts vs matched cryopreserved homografts
Design
Prospective multi-centre study and matched registry analysis
Follow-up
Median 5.9 years
Authors
Loading...
Decellularized homografts were associated with superior explantation-free survival; supports further study but should not yet change practice.
Cohort (n=638)
Yes
Does pulmonary valve replacement using decellularized pulmonary homografts improve freedom from explantation compared to cryopreserved homografts?
Absolute Event Rate: 95.5% vs 83%
p-value: p=<0.001
Decellularized pulmonary homografts demonstrate excellent midterm performance and significantly better freedom from explantation compared to cryopreserved homografts for pulmonary valve replacement.
Bobylev et al. (2022) conducted a cohort in Pulmonary valve replacement (n=638). Decellularized pulmonary homografts (DPH) vs. Cryopreserved homografts (CH) was evaluated on Freedom from explantation (p=<0.001). Decellularized pulmonary homografts demonstrated significantly better freedom from explantation compared to cryopreserved homografts (95.5% vs 83.0%, P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: